Format
Items per page
Sort by

Send to:

Choose Destination

Results: 19

1.

4-[18F]Fluorobenzoyl-Phe-Ala-Leu-Gly-Glu-Ala-NH2.

Leung K.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2011 Aug 26 [updated 2011 Dec 08].

2.

Complement-mediated tumor-specific cell lysis by antibody combinations targeting epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII).

Klausz K, Berger S, Lammerts van Bueren JJ, Derer S, Lohse S, Dechant M, van de Winkel JG, Peipp M, Parren PW, Valerius T.

Cancer Sci. 2011 Oct;102(10):1761-8. doi: 10.1111/j.1349-7006.2011.02019.x. Epub 2011 Aug 4.

PMID:
21718386
3.

[177Lu]-Labeled [(R)-2-amino-3-(4-isothiocyanatophenyl)propyl]-trans-(S,S)-cyclohexane-1,2-diamine-pentaacetic acid (CHX-A″-DTPA) conjugated monoclonal antibody L8A4 against epidermal growth factor receptor variant III (EGFRvIII).

Chopra A.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2010 Dec 24 [updated 2011 Feb 17].

4.

[125I]-Labeled monoclonal antibody L8A4 against epidermal growth factor receptor variant III (EGFRvIII).

Chopra A.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2010 Dec 24 [updated 2011 Feb 17].

5.

[177Lu]-Labeled 2-(4-isothiocyanatobenzyl)-6-methyldiethylene-triaminepentaacetic acid (1B4M-DTPA) conjugated monoclonal antibody L8A4 against epidermal growth factor receptor variant III (EGFRvIII).

Chopra A.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2010 Dec 24 [updated 2011 Feb 17].

6.

[177Lu]-Labeled (S-2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane-tetraacetic acid (C-DOTA) conjugated monoclonal antibody L8A4 against epidermal growth factor receptor variant III (EGFRvIII).

Chopra A.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2010 Dec 24 [updated 2011 Feb 17].

7.

[177Lu]-Labeled α-(5-isothiocyanato-2-methoxyphenyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (MeO-DOTA) conjugated monoclonal antibody L8A4 against epidermal growth factor receptor variant III (EGFRvIII).

Chopra A.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2010 Dec 24 [updated 2011 Feb 17].

8.

<sup>111</sup>In-Labeled chimeric monoclonal antibody, ch806, targeting the epidermal growth factor receptor deletion variant de2-7 (EGFRvIII).

Chopra A.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2010 Jul 06 [updated 2010 Aug 26].

9.

<sup>125</sup>I-Labeled chimeric monoclonal antibody, ch806, targeting the epidermal growth factor receptor deletion variant de2-7 (EGFRvIII).

Chopra A.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2010 Jul 06 [updated 2010 Aug 26].

10.

<sup>124</sup>I-Labeled residulizing ligand IMP-R4 conjugated chimeric monoclonal antibody ch806 targeting the epidermal growth factor receptor deletion variant de2-7 (EGFRvIII).

Chopra A.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2010 Jun 26 [updated 2010 Aug 05].

11.

125I-Labeled monoclonal antibody (mAb) 806 targeting the epidermal growth factor receptor deletion variant de2-7 (EGFRvIII).

Chopra A.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2010 Jul 01 [updated 2010 Aug 05].

12.

111In-Labeled CHX-A”-DTPA conjugated monoclonal antibody (mAb) 806 targeting the epidermal growth factor receptor deletion variant de2-7 (EGFRvIII).

Chopra A.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2010 Jul 01 [updated 2010 Aug 05].

13.

Identification and characterization of Ch806 mimotopes.

Yang L, Jiang H, Shi B, Wang H, Li J, Wang H, Yao M, Li Z.

Cancer Immunol Immunother. 2010 Oct;59(10):1481-7. doi: 10.1007/s00262-010-0872-7. Epub 2010 Jun 11.

PMID:
20544195
14.

Immuno-PET quantitation of de2-7 epidermal growth factor receptor expression in glioma using 124I-IMP-R4-labeled antibody ch806.

Lee FT, O'Keefe GJ, Gan HK, Mountain AJ, Jones GR, Saunder TH, Sagona J, Rigopoulos A, Smyth FE, Johns TG, Govindan SV, Goldenberg DM, Old LJ, Scott AM.

J Nucl Med. 2010 Jun;51(6):967-72. doi: 10.2967/jnumed.109.068395. Epub 2010 May 19.

15.

Cetuximab and other anti-epidermal growth factor receptor monoclonal antibodies in the treatment of non-small cell lung cancer.

Gridelli C, Maione P, Ferrara ML, Rossi A.

Oncologist. 2009 Jun;14(6):601-11. doi: 10.1634/theoncologist.2008-0153. Epub 2009 May 29. Review.

16.

ErbB-directed immunotherapy: antibodies in current practice and promising new agents.

Friedländer E, Barok M, Szöllosi J, Vereb G.

Immunol Lett. 2008 Mar 15;116(2):126-40. doi: 10.1016/j.imlet.2007.12.001. Epub 2007 Dec 26. Review. Erratum in: Immunol Lett. 2009 May 14;124(1):55-6.

PMID:
18201769
17.

A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors.

Scott AM, Lee FT, Tebbutt N, Herbertson R, Gill SS, Liu Z, Skrinos E, Murone C, Saunder TH, Chappell B, Papenfuss AT, Poon AM, Hopkins W, Smyth FE, MacGregor D, Cher LM, Jungbluth AA, Ritter G, Brechbiel MW, Murphy R, Burgess AW, Hoffman EW, Johns TG, Old LJ.

Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4071-6. Epub 2007 Feb 28. Erratum in: Proc Natl Acad Sci U S A. 2007 Oct 2;104(40):15965. Ritter, Gerd [added].

18.

Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR.

Panousis C, Rayzman VM, Johns TG, Renner C, Liu Z, Cartwright G, Lee FT, Wang D, Gan H, Cao D, Kypridis A, Smyth FE, Brechbiel MW, Burgess AW, Old LJ, Scott AM.

Br J Cancer. 2005 Mar 28;92(6):1069-77.

19.

Generation of anti-idiotype antibodies for application in clinical immunotherapy laboratory analyses.

Liu Z, Panousis C, Smyth FE, Murphy R, Wirth V, Cartwright G, Johns TG, Scott AM.

Hybrid Hybridomics. 2003 Aug;22(4):219-28.

PMID:
14511567
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk